Herrmann, R; Bodoky, G; Ruhstaller, T; Glimelius, B; Bajetta, E; Schüller, J; Saletti, P; Bauer, J; Figer, A; Pestalozzi, B; Köhne, CH; Mingrone, W; Stemmer, SM; Tàmas, K; Kornek, GV; Koeberle, D; Cina, S; Bernhard, J; Dietrich, D; Scheithauer, W; ... (2007). Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. Journal of clinical oncology, 25(16), pp. 2212-7. Alexandria, Va.: American Society of Clinical Oncology 10.1200/JCO.2006.09.0886
Full text not available from this repository.This phase III trial compared the efficacy and safety of gemcitabine (Gem) plus capecitabine (GemCap) versus single-agent Gem in advanced/metastatic pancreatic cancer.
Item Type: |
Journal Article (Original Article) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Medical Oncology |
UniBE Contributor: |
Bernhard, Jürg Theodor |
ISSN: |
0732-183X |
ISBN: |
17538165 |
Publisher: |
American Society of Clinical Oncology |
Language: |
English |
Submitter: |
Factscience Import |
Date Deposited: |
04 Oct 2013 14:53 |
Last Modified: |
02 Mar 2023 23:22 |
Publisher DOI: |
10.1200/JCO.2006.09.0886 |
PubMed ID: |
17538165 |
Web of Science ID: |
000247010400012 |
URI: |
https://boris.unibe.ch/id/eprint/22395 (FactScience: 34517) |
Actions (login required)
 |
Edit item |